Evotec SE Share Price Other OTC
Equities
EVTCY
US30050E1055
Biotechnology & Medical Research
Sales 2024 * | 883M 944M 74.65B | Sales 2025 * | 1.04B 1.11B 87.77B | Capitalization | 1.48B 1.58B 125B |
---|---|---|---|---|---|
Net income 2024 * | -28M -29.93M -2.37B | Net income 2025 * | 31M 33.14M 2.62B | EV / Sales 2024 * | 1.93 x |
Net Debt 2024 * | 227M 243M 19.2B | Net Debt 2025 * | 186M 199M 15.78B | EV / Sales 2025 * | 1.6 x |
P/E ratio 2024 * |
-53.3
x | P/E ratio 2025 * |
31.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 06/02/23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 30/04/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 18/06/19 |
Chairman | 63 | 16/06/14 |
1st Jan change | Capi. | |
---|---|---|
+34.14% | 51.51B | |
-6.54% | 39.03B | |
+34.92% | 38.91B | |
-12.11% | 26.68B | |
+12.62% | 26.13B | |
-13.43% | 19.91B | |
+43.73% | 13.71B | |
+31.81% | 12.38B | |
-4.54% | 11.74B |